Company profile

Ticker
ABBV
Exchange
Website
CEO
Richard A. Gonzalez
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
320375147

ABBV stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 Aug 20
21 Sep 20
31 Dec 20

News

Quarter (USD) Jun 20 Mar 20 Sep 19 Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from AbbVie earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
7 Jul 20 Carlos Alban Common Stock, $0.01 par value Sell Dispose S No 100 23,000 2.3M 114,899
7 Jul 20 Carlos Alban Common Stock, $0.01 par value Sell Dispose S No 100.0018 30,325 3.03M 137,899
30 Jun 20 Alpern Robert J Stock Equivalent Units Common Stock Grant Aquire A No 98.18 71 6.97K 7,353
30 Jun 20 Liddy Edward M Stock Equivalent Units Common Stock Grant Aquire A No 98.18 335 32.89K 26,288
30 Jun 20 Edward J Rapp Stock Equivalent Units Common Stock Grant Aquire A No 98.18 350 34.36K 18,108
12 May 20 Jeffrey Ryan Stewart Common Stock, $0.01 par value Sell Dispose S No 90.0022 23,024 2.07M 52,760
68.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2237 2087 +7.2%
Opened positions 249 148 +68.2%
Closed positions 99 164 -39.6%
Increased positions 1176 941 +25.0%
Reduced positions 636 774 -17.8%
13F shares
Current Prev Q Change
Total value 154.61B 80.85B +91.2%
Total shares 1.2B 1.06B +13.0%
Total puts 18.5M 19.45M -4.9%
Total calls 16.92M 16.64M +1.7%
Total put/call ratio 1.1 1.2 -6.4%
Largest owners
Shares Value Change
Vanguard 147.39M $14.47B +17.3%
BLK BlackRock 123.36M $12.11B +21.7%
STT State Street 79.73M $7.83B +16.8%
Capital Research Global Investors 46.1M $4.53B -6.4%
N Price T Rowe Associates 41.78M $4.1B -2.7%
FMR 31.37M $3.08B -10.4%
Geode Capital Management 28.96M $2.84B +12.4%
JPM JPMorgan Chase & Co. 28.65M $2.81B +27.7%
NTRS Northern Trust 24.15M $2.37B +18.7%
Nuveen Asset Management 22.12M $2.17B +45.9%
Largest transactions
Shares Bought/sold Change
BLK BlackRock 123.36M +21.97M +21.7%
Vanguard 147.39M +21.79M +17.3%
STT State Street 79.73M +11.5M +16.8%
Nuveen Asset Management 22.12M +6.96M +45.9%
JPM JPMorgan Chase & Co. 28.65M +6.21M +27.7%
Arrowstreet Capital, Limited Partnership 33K -5.72M -99.4%
Renaissance Technologies 19.02M +5.47M +40.3%
JHG Janus Henderson 16.39M +4.87M +42.3%
NTRS Northern Trust 24.15M +3.81M +18.7%
FMR 31.37M -3.64M -10.4%

Financial report summary

?
Risks
  • The expiration or loss of patent protection and licenses may adversely affect AbbVie's future revenues and operating earnings.
  • AbbVie's major products could lose patent protection earlier than expected, which could adversely affect AbbVie's future revenues and operating earnings.
  • AbbVie's research and development efforts may not succeed in developing and marketing commercially successful products and technologies, which may cause its revenues and profitability to decline.
  • AbbVie's biologic products are subject to competition from biosimilars.
  • Significant safety or efficacy issues could arise for AbbVie's products, which could have a material adverse effect on AbbVie's revenues and financial condition.
  • AbbVie is subject to numerous governmental regulations, and it can be costly to comply with these regulations and to develop compliant products and processes.
  • AbbVie is dependent on wholesale distributors for distribution of its products in the United States and, accordingly, its results of operations could be adversely affected if they encounter financial difficulties.
  • AbbVie has debt obligations that could adversely affect its business and its ability to meet its obligations.
  • Failure to attract and retain highly qualified personnel could affect AbbVie’s ability to successfully develop and commercialize products.
  • The pending acquisition of Allergan may not be completed on the currently contemplated timeline or terms, or at all, and may not achieve the intended benefits.
  • The indebtedness of the combined company following the consummation of the Acquisition will be substantially greater than AbbVie’s indebtedness on a standalone basis and greater than the combined indebtedness of AbbVie and Allergan prior to the announcement of the acquisition. This increased level of indebtedness could adversely affect the combined company’s business flexibility and increase its borrowing costs.
Management Discussion
  • AbbVie's strategy has focused on delivering strong financial results, advancing and investing in its pipeline and returning value to shareholders while ensuring a strong, sustainable growth business over the long term. The company's financial performance in 2019 included delivering worldwide net revenues of $33.3 billion, operating earnings of $13.0 billion, diluted earnings per share of $5.28 and cash flows from operations of $13.3 billion. Worldwide net revenues grew by 3% on a constant currency basis, primarily driven by revenue growth related to IMBRUVICA and VENCLEXTA as well as the continued strength of HUMIRA in the U.S. and newly launched immunology assets SKYRIZI and RINVOQ, offset by international HUMIRA biosimilar competition.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: abicipar, administered, advisory, aesthetic, age, American, antagonist, anticompetitive, area, atogepant, atopic, attributable, Aurobindo, BioMed, bipolar, bispecific, BLA, bladder, BNP, BofA, Botox, botulinum, calcitonin, cariprazine, cease, Center, cerebral, chin, Citigroup, CODM, compound, comprised, contributory, conversion, converted, Cosmetic, creation, CRL, cycle, Cyclosporine, Daewoong, DARPin, deductible, degeneration, desist, detrusor, discovery, dose, Emulsion, epcoritamab, established, estradiol, facial, failure, false, Fargo, Forest, forma, full, Gedeon, Genentech, Genmab, geographic, Group, Harbour, improperly, inclusive, inflammation, infringe, intraocular, ITC, Japan, Jersey, Jeuveau, jointly, judge, Juvederm, lattice, Letter, limb, longer, MAA, macular, maker, mania, maximizing, Medytox, member, migraine, Mizuho, modification, muscle, nAMD, Namenda, Namzaric, Native, neovascular, neurotoxin, norethindrone, occurrence, Ophthalmic, Opiate, opioid, optimize, ordinary, Oriahnn, overactivity, partnership, pediatric, pegol, peptide, permanent, Perrigo, petitioning, preliminarily, prescribing, prescription, pro, proceed, promoted, promptly, ratio, reached, reduction, region, resolved, Richter, Roche, sBLA, schizophrenia, segment, Silbersher, sNDA, solve, sought, spasticity, statewide, strategic, Supreme, technique, textured, today, tomorrow, Ultra, underlying, University, unused, urology, Utrecht, valuation, Voluma, Vraylar, wet, XC, XR, York
Removed: affirmed, amended, announcement, augment, autoimmune, beneficial, bring, capable, charitable, commenced, consisting, consummation, defendant, dermatology, disease, diversifying, drawn, emerging, gastroenterology, heading, hereto, HIV, immunodeficiency, issuing, launch, metabolic, neurological, option, pain, Parkinson, promising, pursue, restated, restrictive, rheumatology, ruled, scope, thyroid, treating, virology

Patents

APP
Utility
Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors
17 Sep 20
Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
APP
Utility
Ectonucleotide Pyrophosphatase-phosphodiesterase 1 (ENPP-1) Inhibitors and Uses Thereof
17 Sep 20
Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo.
APP
Utility
Tetracyclic Bromodomain Inhibitors
17 Sep 20
Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
APP
Utility
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
17 Sep 20
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
GRANT
Utility
Glucocorticoid receptor agonist and immunoconjugates thereof
15 Sep 20
Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same.